Immunicum AB (publ) Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors (GIST)

What we doOur approachPipelineTechnologyPublications
About usExecutive ManagementBoard of DirectorsScientific Advisory Board
News & eventsPress releasesEventsInterviews
Investors
Careers

Back
Immunicum AB (publ) Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors (GIST)
 8:00:00 AM

Keep reading
Immunicum AB (publ) Announces Year-End Results 2020Read